Incyte Crumbles As Light Opzelura Guide Undoes Quarterly Sales Beat

Core Viewpoint - Incyte's stock declined significantly due to lower-than-expected sales guidance for its product Opzelura, overshadowing a revenue beat in the fourth quarter [1] Group 1: Company Performance - Incyte projected Opzelura sales for 2026 to be between $750 million and $790 million, which is below analysts' expectations of $816 million to $819 million [1] - The decline in stock price occurred despite the company reporting a revenue beat for the fourth quarter [1] Group 2: Product Information - Opzelura is a steroid-free cream designed for treating skin conditions [1]